Immune System News and Research

RSS

AlloSource's AlloWrap DS amniotic membrane moved to high-cost reimbursement category

AlloSource, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced that AlloWrap DS, its double-sided human amniotic membrane allograft, has been moved to the high-cost reimbursement category.

29 May 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

29 May 2015

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.

29 May 2015

iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics, today reported financial results for the quarter ended March 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 May 2015

Novel discovery offers new insight into why women more likely than men to develop MS

An innocent mistake made by a graduate student in a Northwestern Medicine lab (she accidentally used male mice instead of female mice during an experiment) has led scientists to a novel discovery that offers new insight into why women are more likely than men to develop autoimmune diseases such as multiple sclerosis (MS).

28 May 2015

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

A new collaborative study led by researchers at Sanford-Burnham Medical Research Institute, published today in Cell Reports, provides new insight into the molecular changes that lead to resistance to a commonly prescribed group of drugs called BRAF inhibitors.

28 May 2015

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients.

28 May 2015

Novel survey shows high rates of tattoo-related infection, itching and swelling in New Yorkers

In what they believe to be the first survey of its kind in the United States, researchers at NYU Langone Medical Center have found that as many as 6 percent of adult New Yorkers who get "inked" — in other words, those who get a tattoo — have experienced some form of tattoo-related rash, severe itching or swelling that lasted longer than four months and, in some cases, for many years.

28 May 2015

Research findings could help guide development of potential treatments for HCV

Warring armies use a variety of tactics as they struggle to gain the upper hand. Among their tricks is to attack with a decoy force that occupies the defenders while an unseen force launches a separate attack that the defenders fail to notice.

28 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Earlier antiretroviral treatment benefits HIV-infected individuals

A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count--a key measure of immune system health--is higher, instead of waiting until the CD4+ cell count drops to lower levels. Together with data from previous studies showing that antiretroviral treatment reduced the risk of HIV transmission to uninfected sexual partners, these findings support offering treatment to everyone with HIV.

28 May 2015

New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of stem cells, was found to provide pain relief and to reduce the severity of this skin condition for which no cure currently exists.

27 May 2015

Study: Drugs that block NPC1 protein could be used to treat Ebola virus disease

A new study has demonstrated that a protein called Niemann-Pick C1 (NPC1) is critical for the Ebola virus to infect a host. The study, published in the May/June issue of mBio, the online open-access journal of the American Society for Microbiology, suggests that drugs that block NPC1 could be used to treat this deadly disease.

27 May 2015

Risk for obesity-associated diseases significantly higher for males than females

Obesity may be tougher on male immune systems than females, a new study in mice at the University of Michigan Medical School suggests.

27 May 2015

Study indicates that arthritis patients may not be taking medication as regularly as prescribed

Researchers from the Arthritis Research UK Centre for Epidemiology at The University of Manchester found that 40% of patients scored low on an adherence questionnaire at least once during their time in a recent study, indicating that they might not be taking their expensive biological therapies as regularly as prescribed.

26 May 2015

Treatment outcomes in type 1 diabetes could be improved across all age groups

In a sweeping analysis assessing the current state of diabetes treatment in the U.S., T1D Exchange researchers conclude that there remains considerable room for improving treatment outcomes in type 1 diabetes across all age groups, but especially for adolescents and young adults.

22 May 2015

Microfluidic cell-squeezing device could introduce specific antigens inside immune system's B cells

MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune system's B cells, providing a new approach to developing and implementing antigen-presenting cell vaccines.

22 May 2015

Breakthrough in fight against rare kidney disease - Membranous Nephropathy

Scientists at The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust have made a significant breakthrough in the fight against Membranous Nephropathy (MN) - a rare kidney disease which can lead to kidney failure.

22 May 2015

TGen and Baylor partnership set to increase treatment options for cancer patients

The Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) at Dallas today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.

22 May 2015

Study explores how our intestinal tract changes as we age

Scientists and clinicians on the Norwich Research Park have carried out the first detailed study of how our intestinal tract changes as we age, and how this determines our overall health.

22 May 2015

Immune System News and Research

AlloSource's AlloWrap DS amniotic membrane moved to high-cost reimbursement category

Monoclonal antibody nivolumab improves survival rates of melanoma patients

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

iCo Therapeutics reports financial results for first quarter 2015

Novel discovery offers new insight into why women more likely than men to develop MS

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

Novel survey shows high rates of tattoo-related infection, itching and swelling in New Yorkers

Research findings could help guide development of potential treatments for HCV

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Earlier antiretroviral treatment benefits HIV-infected individuals

New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

Study: Drugs that block NPC1 protein could be used to treat Ebola virus disease

Risk for obesity-associated diseases significantly higher for males than females

Study indicates that arthritis patients may not be taking medication as regularly as prescribed

Treatment outcomes in type 1 diabetes could be improved across all age groups

Microfluidic cell-squeezing device could introduce specific antigens inside immune system's B cells

Breakthrough in fight against rare kidney disease - Membranous Nephropathy

TGen and Baylor partnership set to increase treatment options for cancer patients

Study explores how our intestinal tract changes as we age

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News